Advanced search
Start date
Betweenand

On malaria susceptibility: investigating the resistance mechanisms of novel antimalarials and deciphering the physiopathological factors related to recurrence risk in Plasmodium vivax malaria.

Abstract

Nearly half of the world's population is at risk of contracting malaria. With almost 250 million cases reported in 2022, malaria is a disease that still imposes a heavy burden upon populations at risk, especially in tropical and developing countries. Beyond the 608 thousand annual malaria-related deaths, the disease also significantly impacts overall health and quality of life, overwhelming public health systems and causing economic losses 1-3. The Plasmodium vivax life cycle involves multiple hidden compartments in the human host that are challenging to detect and identify, including dormant liver stages (hypnozoites), whose activation leads to a new malarial episode. Additionally, its proclivity to invade young red blood cells (reticulocytes) results in infections that may occur in privileged hematopoietic niches (e.g., bone marrow) rather than peripheral blood (PB) circulation. Furthermore, the early and continuous production of mosquito-infective sexual forms (gametocytes) not only allows for a high transmission potential but also expands the parasite's reach beyond seasonal and geographical boundaries, representing a significant challenge to malaria elimination efforts 4,5. Recent data from single-cell transcriptome analysis scRNA-seq) have shown the early sexual commitment of parasites still in their dormant liver stage, suggesting the expression of AP2-G, a master regulator of gametocytogenesis, as a mechanism 6shared between gametocytes and hypnozoites. Furthermore, the same study indicates that a deficiency of metabolites such as iron or specific types of lipids is related to both liver quiescence and sexual differentiation in P. vivax 6-8. Importantly, 90% of vivax malaria cases are due to recurrences 9, which10, along with gametocyte transmission, even before the onset of symptoms, calls not only for novel chemoprevention and transmission-blocking therapies but also for reliable indicators to help link recurrence rates and transmission dynamics in endemic areas. Even though reduced CYP2D6 activity 10, high gametocytemia 11, and inadequate/discontinued primaquine therapy 12,13 have been proposed to modulate recurrence susceptibility, it is unclear what drives the recurrence risk when these factors are controlled. Identifying, through a multi-omics approach, host or parasite factors related to recurrences in vivax malaria may guide new treatment and transmission control strategies. Furthermore, studying the interplay between the biology of the main parasite forms, such as gametocytes, and their developmental niches will guide the discovery of new molecular targets 14-19. Hence, given the complex host-parasite interaction, we believe that assessing the susceptibility/risk of individuals to recurrence, as well as understanding the mechanisms associated with parasite resistance to new molecules effective in combating the different parasite forms, will allow us to integrate efforts to improve the epidemiology, prevention, and control strategies for vivax malaria. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
More itemsLess items
Articles published in other media outlets ( ):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)